Atlas Trials

A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT06423885 · RECRUITING

Trial details

NCT number
NCT06423885
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Start date
2024-12-24
Primary completion
2026-10-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.